APP and Alzheimer disease: In AD-endophenotype APP transgenic mouse models, though limited in regard to physiological context for APP expression, it has been widely demonstrated that elevated levels of soluble oligomeric Aβ drive LTP inhibition (Cullen et al., 1997; Chapman et al., 1999; Walsh et al., 2002; Kimura and Ohno, 2009), coupled to downregulation of synaptic AMPARs.